Application of oncolytic virus therapy in colorectal cancer

doi:10.3877/cma.j.issn.1674-0793.2023.05.013

Abstract

Abstract:

As a branch of immunotherapy, oncolytic virus therapy has become a research hotspot in recent years. Oncolytic virus mainly achieves anti-tumor effect by inducing specific immune response through targeted lysis of tumor cells. Oncolytic viruses can also be combined with radiotherapy and chemotherapy, immunosuppressive agents to reprogram tumor microenvironment and enhance anti-tumor effects. This article reviews the application and mechanism of commonly used oncolytic viruses in colorectal cancer.

Key words: Oncolytic therapy, Colorectal neoplasms, Immunotherapy

Yongting Xue, Feng Gao, Yanan Wang, Lianping Qu. Application of oncolytic virus therapy in colorectal cancer[J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(05): 380-384.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2023.05.013

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2023/V17/I05/380

Figures/Tables 1

References 42

[1]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2]	Liu S, Zheng R, Zhang M, et al. Incidence and mortality of colorectal cancer in China, 2011[J]. Chin J Cancer Res, 2015, 27(1): 22-28.
[3]	Yoo SY, Bang SY, Jeong SN, et al. A cancer-favoring oncolytic vaccinia virus shows enhanced suppression of stem-cell like colon cancer[J]. Oncotarget, 2016, 7(13): 16479-16489.
[4]	Nakatake M, Kuwano N, Kaitsurumaru E, et al. Fusogenic oncolytic vaccinia virus enhances systemic antitumor immune response by modulating the tumor microenvironment[J]. Mol Ther, 2021, 29(5): 1782-1793.
[5]	Deng L, Yang X, Fan J, et al. IL-24-armed oncolytic vaccinia virus exerts potent antitumor effects via multiple pathways in colorectal cancer[J]. Oncol Res, 2021, 28(6): 579-590.
[6]	Samson A, West EJ, Carmichael J, et al. Neoadjuvant intravenous oncolytic vaccinia virus therapy promotes anticancer immunity in patients[J]. Cancer Immunol Res, 2022, 10(6): 745-756.
[7]	Downs-Canner S, Guo ZS, Ravindranathan R, et al. Phase 1 study of intravenous oncolytic Poxvirus (vvDD) in patients with advanced solid cancers[J]. Mol Ther, 2016, 24(8): 1492-1501.
[8]	Park SH, Breitbach CJ, Lee J, et al. Phase 1b trial of biweekly intravenous Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus in colorectal cancer[J]. Mol Ther, 2015, 23(9): 1532-1540.
[9]	Xiao B, Zhang L, Liu H, et al. Oncolytic adenovirus CD55-Smad4 suppresses cell proliferation, metastasis, and tumor stemness in colorectal cancer by regulating Wnt/β-Catenin signaling pathway[J]. Biomedicines, 2020, 8(12): 593.
[10]	Guo Y, Zhang Z, Xu X, et al. Menstrual blood-derived stem cells as delivery vehicles for oncolytic adenovirus virotherapy for colorectal cancer[J]. Stem Cells Dev, 2019, 28(13): 882-896.
[11]	Gao H, Zhang X, Ding Y, et al. Synergistic suppression effect on tumor growth of colorectal cancer by combining radiotherapy with a trail-armed oncolytic adenovirus[J]. Technol Cancer Res Treat, 2019, 18: 1533033819853290.
[12]	Jessup JM, Kabbout M, Korokhov N, et al. Adenovirus and oxaliplatin cooperate as agnostic sensitizers for immunogenic cell death in colorectal carcinoma[J]. Hum Vaccin Immunother, 2020, 16(3): 636-644.
[13]	Fabian KP, Malamas AS, Padget MR, et al. Therapy of established tumors with rationally designed multiple agents targeting diverse immune-tumor interactions: engage, expand, enable[J]. Cancer Immunol Res, 2021, 9(2): 239-252.
[14]	Sun K, Xu Y, Zhang L, et al. A phase 2 trial of enhancing immune checkpoint blockade by stereotactic radiation and in situ virus gene therapy in metastatic triple-negative breast cancer[J]. Clin Cancer Res, 2022, 28(20): 4392-4401.
[15]	Gállego Pérez-Larraya J, Garcia-Moure M, Labiano S, et al. Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma[J]. N Engl J Med, 2022, 386(26): 2471-2481.
[16]	Seiwert TY, Darga T, Haraf D, et al. A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation[J]. Ann Oncol, 2013, 24(3): 769-776.
[17]	Freytag SO, Stricker H, Lu M, et al. Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer[J]. Int J Radiat Oncol Biol Phys, 2014, 89(2): 268-276.
[18]	Palmer CD, Rappaport AR, Davis MJ, et al. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results[J]. Nat Med, 2022, 28(8): 1619-1629.
[19]	Garcia-Carbonero R, Salazar R, Duran I, et al. Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection[J]. J Immunother Cancer, 2017, 5(1): 71.
[20]	Sze DY, Iagaru AH, Gambhir SS, et al. Response to intra-arterial oncolytic virotherapy with the herpes virus NV1020 evaluated by [18F]fluorodeoxyglucose positron emission tomography and computed tomography[J]. Hum Gene Ther, 2012, 23(1): 91-97.
[21]	Geevarghese SK, Geller DA, de Haan HA, et al. Phase Ⅰ/Ⅱ study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver[J]. Hum Gene Ther, 2010, 21(9): 1119-1128.
[22]	Zhang W, Zeng B, Hu X, et al. Oncolytic herpes simplex virus type 2 can effectively inhibit colorectal cancer liver metastasis by modulating the immune status in the tumor microenvironment and inducing specific antitumor immunity[J]. Hum Gene Ther, 2021, 32(3-4): 203-215.
[23]	Zhang W, Wang F, Hu X, et al. Inhibition of colorectal cancer liver metastasis in BALB/c mice following intratumoral injection of oncolytic herpes simplex virus type 2 for the induction of specific antitumor immunity[J]. Oncol Lett, 2019, 17(1): 815-822.
[24]	Haghighi-Najafabadi N, Roohvand F, Shams Nosrati MS, et al. Oncolytic herpes simplex virus type-1 expressing IL-12 efficiently replicates and kills human colorectal cancer cells[J]. Microb Pathog, 2021, 160: 105164.
[25]	Wu Z, Ichinose T, Naoe Y, et al. Combination of cetuximab and oncolytic virus canerpaturev synergistically inhibits human colorectal cancer growth[J]. Mol Ther Oncolytics, 2019, 13: 107-115.
[26]	Zhou X, Zhao J, Zhang JV, et al. Enhancing Therapeutic efficacy of oncolytic herpes simplex virus with MEK inhibitor trametinib in some BRAF or KRAS-mutated colorectal or lung carcinoma models[J]. Viruses, 2021, 13(9): 1758.
[27]	Shayan S, Arashkia A, Bahramali G, et al. Cell type-specific response of colon cancer tumor cell lines to oncolytic HSV-1 virotherapy in hypoxia[J]. Cancer Cell Int, 2022, 22(1): 164.
[28]	王凤娇, 韩继武, 王大秀. 荷IL-12新城疫病毒治疗结肠癌的实验及其机制探讨[J].现代肿瘤医学, 2021, 29(5): 761-765.
[29]	Meng F, Cao Y, Su H, et al. Newcastle disease virus expressing an angiogenic inhibitor exerts an enhanced therapeutic efficacy in colon cancer model[J]. PLoS One, 2022, 17(4): e0264896.
[30]	Tian L, Liu T, Jiang S, et al. Oncolytic Newcastle disease virus expressing the co-stimulator OX40L as immunopotentiator for colorectal cancer therapy[J]. Gene Ther, 2023, 30(1-2): 64-74.
[31]	梁莹, 黄盼柳, 樊晓晖, 等. 新城疫病毒7793对结肠癌肝转移模型小鼠肝内Th1、Th2、Th17类细胞因子表达的影响[J]. 肿瘤学杂志, 2016, 22(5): 355-359.
[32]	古丽娜儿, 王思橦, 黄莉莉, 等.新城疫病毒诱导结肠癌Caco2细胞株发生Caspase和p38MAPK依赖性诱凋亡[J]. 同济大学学报(医学版), 2020, 41(5): 546-551.
[33]	Li Q, Wei D, Feng F, et al. α2,6-linked sialic acid serves as a high-affinity receptor for cancer oncolytic virotherapy with Newcastle disease virus[J]. J Cancer Res Clin Oncol, 2017, 143(11): 2171-2181.
[34]	Schulze T, Kemmner W, Weitz J, et al. Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial[J]. Cancer Immunol Immunother, 2009, 58(1): 61-69.
[35]	Sharifi N, Soleimanjahi H, Mokhtari-Dizaji M, et al. Low-intensity ultrasound as a novel strategy to improve the cytotoxic effect of oncolytic reovirus on colorectal cancer model cells[J]. Intervirology, 2022, 65(2): 110-118.
[36]	Babaei A, Soleimanjahi H, Soleimani M, et al. The synergistic anticancer effects of ReoT3D, CPT-11, and BBI608 on murine colorectal cancer cells[J]. Daru, 2020, 28(2): 555-565.
[37]	Jiffry J, Thavornwatanayong T, Rao D, et al. Oncolytic reovirus (pelareorep) induces autophagy in KRAS-mutated colorectal cancer[J]. Clin Cancer Res, 2021, 27(3): 865-876.
[38]	Maitra R, Seetharam R, Tesfa L, et al. Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan[J]. Oncotarget, 2014, 5(9): 2807-2819.
[39]	Maitra R, Augustine T, Dayan Y, et al. Toll like receptor 3 as an immunotherapeutic target for KRAS mutated colorectal cancer[J]. Oncotarget, 2017, 8(21): 35138-35153.
[40]	Babaei A, Soleimanjahi H, Soleimani M, et al. Mesenchymal stem cells loaded with oncolytic reovirus enhances antitumor activity in mice models of colorectal cancer[J]. Biochem Pharmacol, 2021, 190: 114644.
[41]	Parakrama R, Fogel E, Chandy C, et al. Immune characterization of metastatic colorectal cancer patients post reovirus administration[J]. BMC Cancer, 2020, 20(1): 569.
[42]	Jonker DJ, Tang PA, Kennecke H, et al. A randomized phase Ⅱ study of FOLFOX6/bevacizumab with or without pelareorep in patients with metastatic colorectal cancer: IND.210, a Canadian Cancer Trials Group trial[J]. Clin Colorectal Cancer, 2018, 17(3): 231-239, e7.

病毒	类型	大小(nm)	包膜	临床研究试验编号	试验对象	随访时间(月)	试验结果
痘苗病毒	双链DNA病毒	(300~450)×(170~260)^a	有	NCT04194034	结直肠癌肝转移瘤或转移性黑色素瘤患者^[6]	36	9例中存活5例（55.6%）
腺病毒	双链DNA病毒	70~90^a	无	NCT02053220	结直肠癌患者^[19]	16	病毒在肿瘤样本中复制，在正常组织中无活性
疱疹病毒	双链DNA病毒	约120^a	有	NCT00149396	结直肠癌肝转移患者^[20]	6	部分缓解和疾病稳定率分别为6.3%和50.0%
新城疫病毒	单链RNA病毒	100~400^a	有	—	结肠癌肝转移患者^[34]	116	治疗组总生存率优于对照组
呼肠孤病毒	双链RNA病毒	60~80^a	无	NCT01622543	转移性结直肠癌患者^[42]	13	客观缓解率升高

病毒	类型	大小(nm)	包膜	临床研究试验编号	试验对象	随访时间(月)	试验结果
痘苗病毒	双链DNA病毒	(300~450)×(170~260)^a	有	NCT04194034	结直肠癌肝转移瘤或转移性黑色素瘤患者^[6]	36	9例中存活5例（55.6%）
腺病毒	双链DNA病毒	70~90^a	无	NCT02053220	结直肠癌患者^[19]	16	病毒在肿瘤样本中复制，在正常组织中无活性
疱疹病毒	双链DNA病毒	约120^a	有	NCT00149396	结直肠癌肝转移患者^[20]	6	部分缓解和疾病稳定率分别为6.3%和50.0%
新城疫病毒	单链RNA病毒	100~400^a	有	—	结肠癌肝转移患者^[34]	116	治疗组总生存率优于对照组
呼肠孤病毒	双链RNA病毒	60~80^a	无	NCT01622543	转移性结直肠癌患者^[42]	13	客观缓解率升高

Please choose a citation manager

Content to export